RxDoctor Payments DataLook up a doctor →

Mark Greathouse, MD

Cardiovascular Disease · Pittsburgh, PANPI 1093796542

Payments from drug & device makers

$243,085in general payments, 2019–2025

Across 513 payments — averaging $473.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198K
  • Amgen$36K
  • Pfizer$4K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Johnson & Johnson$866
  • plus $2K from 29 others

What the payments were for

  • Consulting fees$17,4657%
  • Speaking & faculty fees$203,46684%
  • Travel & lodging$13,2945%
  • Food & beverage$8,8394%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$243,085 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,559
Medicare patients
576
Services billed
1,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$382,076
EntrestoSacubitril/Valsartan84$90,709
Repatha SureclickEvolocumab70$46,995
XareltoRivaroxaban49$32,395
OzempicSemaglutide11$22,742
JardianceEmpagliflozin26$18,538
BrilintaTicagrelor27$14,601
Metoprolol Succinate524$6,039
Rosuvastatin Calcium322$4,958
Ranolazine ErRanolazine52$3,199
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$3,059
Valsartan78$2,622
Atorvastatin Calcium235$2,229
Spironolactone152$2,014
Amlodipine Besylate353$1,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,591$382,076465 claims
NovartisEntresto$1,025$90,70984 claims
Johnson & JohnsonXarelto$866$32,39549 claims
Novo NordiskOzempic$197,724$22,74211 claims
Boehringer IngelheimJardiance$65$18,53826 claims
AstraZenecaBrilinta$247$14,60127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →